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Background: Germany hosts a large number of refugees from war-affected countries. The integration of refugees,
in particular young refugees from the Middle East, is one of the major current social challenges in Germany. Mental
disorders, first of all post-traumatic stress disorder (PTSD) that results from war experiences, are common among
young refugees and interfere with quality of life as well as functional integration. Evidence regarding effective
treatment options for this population is scarce. In this trial, we aim to evaluate the pragmatic, short-term psychotherapy
Narrative Exposure Therapy for Children (KIDNET) for the treatment of young refugees in Germany.
Methods: In a rater-blinded, multi-center, randomized-controlled trial, KIDNET is compared to treatment as usual (TAU)
within the general health care system. A total number of 80 young refugees who fulfill the diagnostic criteria of PTSD will
be randomized to either KIDNET or TAU. Diagnostic interviews will take place at baseline before treatment as well as 6
and 12months thereafter. They will assess exposure to traumatic events, PTSD and comorbid symptoms, as well as
parameters of integration.
Discussion: The results of this study should provide evidence regarding effective treatment options for young refugees in
Germany, a population that has been understudied and received only limited access to mental health care so far. Next to
the effects of treatment on mental health outcomes, integration parameters will be investigated. Therefore, this study
should provide broad insights into treatment options for young refugees and their potential implications on successful
integration.
Trial registration: German Clinical Trials Register (Deutsches Register Klinischer Studien; DRKS), ID: DRKS00017222.
Registered on 15 May 2019.
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Germany is host to a large number of refugees from
various war-torn countries. In the home countries as
well as on their dangerous journey to Germany, refugees
have experienced numerous traumatic experiences. Since
the likelihood to develop mental health disorders in-
creases with accumulating traumatic events in a dose-
dependent manner [1, 2], a high prevalence of mental
ill-health can be expected in this population, in particu-
lar high rates of post-traumatic stress disorder (PTSD)
and comorbid disorders. So far, evidence regarding the
prevalence rate of mental health disorders of refugees in
Germany is limited. However, an initial study indicates
that approximately one half of refugees living in a
German refugee accommodation were screened positive
for mental health problems [3]. In a representative sam-
ple of Syrian refugee children from a German reception
camp, PTSD was diagnosed in 33% of children aged
7–14 years [4].
Although the majority of trauma survivors recover
without treatment over time, war-related PTSD seems to
be highly persistent [5]. PTSD is characterized by symp-
toms like concentration difficulties, loss of interest in
social activities, insomnia and irritability that involve a
high impairment in everyday functioning [6]. Further-
more, higher PTSD symptom severity is associated with
an increased risk of poor physical health [7]. In addition,
PTSD symptoms in children and adolescents are corre-
lated with neuropsychological dysfunctions in a range of
cognitive tasks [8, 9] as well as with reduced school per-
formance [10]. PTSD symptoms but not trauma expos-
ure are related to reduced intellectual capabilities [9] in
particular in verbal skills [11]. A study with war-affected
children in Sri Lanka found that children with PTSD
presented with lower school grades in language-related
subjects [12]. In a treatment-seeking sample of refugees
in Switzerland, the severity of PTSD symptoms was as-
sociated with social integration difficulties [13]. Taken
together, it is likely that next to the individual suffering,
PTSD symptoms interfere with integration into the host
country, as well as academic achievement. Consistent
with this assumption, a study in Sweden has shown that
Iraqi refugees with PTSD had a significantly delayed
performance in language schools [14]. In the face of the
expectedly high prevalence rate of PTSD in the current
refugee population and the probable interference of
PTSD with integration, the development of effective,
evidence-based and pragmatic treatments for PTSD,
especially for these populations, should be a public
health priority.
Cumulating evidence from clinical studies indicates
that the different variants of the so-called trauma-
focused psychotherapies are the treatments of first
choice for PTSD in children [15]. Trauma-focusedtreatments have in common that they target traumatic
memories through exposure or cognitive interventions.
A recent independent evaluation indicated that, on the
basis of the rationale as well as the available efficacy,
Narrative Exposure Therapy (NET) is probably advan-
tageous for the treatment of traumatized refugees in
comparison to other trauma-focused approaches [16].
However, current evidence is limited with regard to the
treatment of war-affected children with PTSD. The
available knowledge relies on case-series and cohort
studies with only a few exceptional randomized trials.
A systematic literature research in MEDLINE identified
12 published randomized controlled trials (RCTs) with
war-affected children (see Table 1). Out of these, five
studies reported the effectiveness of school-based cog-
nitive behavior therapy (CBT)-like interventions that
did not screen for or exclude children with high values
of PTSD symptoms (four of these did not find a signifi-
cant effect on PTSD symptoms), one screened youths
for distress and did also not find an effect on PTSD,
two applied trauma-focused-CBT in groups and one
applied individual trauma-focused-CBT and found a
significant effect on PTSD. Three trials studied the ef-
fectiveness of Narrative Exposure Therapy for Children
(KIDNET), also with a significant effect on PTSD
symptoms. Only a single RCT studied PTSD treat-
ment (KIDNET) in refugee children [26].
A recent independent review [29] confirmed that, con-
sistent with the literature from war-affected adults [30],
KIDNET is one of the most promising and best-studied
treatment approaches for war-affected children with
PTSD and has generally caused a clinically significant
improvement in treated children.
In the three available KIDNET trials that included
children and adolescents, KIDNET has been compared
to meditation for school children in Sri Lanka [27],
academic counseling and a waiting-list control condition
in former child-soldiers in Uganda [25], as well as a
waiting-list control group in asylum seekers in Germany
[26]. Taken together, these studies show that individual
short-term behavioral interventions can be effective for
the treatment of PTSD across cultural contexts and age
ranges. The three currently available trials of KIDNET
for children and adolescents show that KIDNET is a
safe, efficient and robust treatment that can be imple-
mented in schools [27], communities [25] and outpatient
clinics [26]. However, it is questionable whether the
results from these trials can be easily transferred to the
current situation of young refugees in Germany. The
trial by Catani et al. [27] studied survivors of the war
and the tsunami within 4 weeks after the 2009 tsunami
catastrophe in Sri Lanka and may be considered as an
intervention for acute PTSD rather than chronic war
trauma. The study by Ertl et al. [25] included older
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Wilker et al. Trials          (2020) 21:185 Page 4 of 16adolescents as well as young adults and was restricted to
child soldiers. The trial of Ruf et al. [26] is probably the
most relevant study for the current refugee situation,
since it investigated refugee children who had fled to
Germany. Even though this study is generally methodo-
logically sound, it is characterized by a small sample size
(N = 13 per group) and a limited range of outcome
measures.
Although current evidence suggests that trauma-
focused psychotherapy is probably effective for the treat-
ment of PTSD in war-affected refugee children and ado-
lescents, the provision of effective psychotherapy for
traumatized refugee children is currently not a priority
within the German health care system and there have
been only very limited improvements after the sudden
increased influx of refugees in 2015 [31]. Against this
background, this trial is urgently needed as it may ad-
vance the evidence of the possibilities and limitations of
psychotherapy for PTSD and comorbid disorders in
refugee children and adolescents. In particular, this trial
is characterized by advanced and state-of-the art
methods to reduce bias (multi-center trial, blinding of
assessors, manualized and standardized treatment, fidel-
ity rating, etc.), an extended range of outcome measures,
including depression, physical health, integration param-
eters, as well as limited exclusion parameters to enhance
the external validity of the results.
Aim of the trial
The YOURTREAT trial is part of the study consortium
“Stress, Health and Integration of Young Refugees:
Discovering the Interrelations and Improving Access to
Healthcare (YOURHEALTH)” funded by the German
Federal Ministry of Education and Research (Bundesmi-
nisterium für Bildung und Forschung; BMBF). This
funding agency had no influence on the trial design and
will not influence data collection, data management, data
analyses, interpretation of study results, publication nor
report writing. Within this consortium, the clinical trial
YOURTREAT aims to test whether the treatment of
young refugees (10–18 years) with KIDNET causes an
effective reduction of PTSD and comorbid symptoms. In
more detail, KIDNET will be implemented within an
innovative complementary health care system that is at-
tached to outpatient clinics of universities and university
hospitals. The treatment in the outpatient clinics will be
supported by Intercultural Therapy Assistants (ITAs)
who will interpret the diagnostic interviews and therapy
sessions if required, but can also further support the
therapeutic process by accompanying young refugees on
their way to and from the therapy, or support the
recruitment and eligibility screening into the study. The
treatment with 11 sessions of KIDNET supported by
ITAs will be compared to treatment as usual (TAU) foryoung refugees within the general health care system in
Germany.
The primary hypothesis of this trial is that, 6 and 12
months after randomization, children who received KID-
NET compared to children referred to the regular health
care system in the TAU condition will show a greater
PTSD symptom reduction. The secondary hypothesis
refers to a superiority of KIDNET for the reduction of
comorbid depressive, internalizing and externalizing
symptoms, as well as suicidal ideation and a reduction of
strain caused by discrimination, as well as an improve-
ment of physical health. Furthermore, a lower rate of in-
dividuals who still meet the diagnostic criteria of PTSD
and a greater response rate is expected in the KIDNET
group as opposed to the TAU group.
Methods
Trial design
YOURTREAT is a randomized controlled, rater-blinded,
two-arm, multi-center, superiority trial with a 1:1 alloca-
tion ratio to two parallel groups. Individuals who are
screened eligible for the trial will participate in a com-
prehensive diagnostic interview (t1). Among other infor-
mation (detailed below), this structured interview will
assess the diagnosis of PTSD according to the Diagnostic
and Statistical Manual of Mental Disorders, 5th edition
(DSM-5). We expect that we will have to interview ap-
proximately N = 220 children and adolescents (N = 55
per site) in order to identify 80 participants (N = 20 per
site) who fulfill the diagnostic criteria of PTSD. These
PTSD patients will be immediately randomized to one of
the two arms of the trial; KIDNET or TAU. For individ-
uals included in the KIDNET group, the treatment starts
within 1 month after the diagnostic interview and should
be terminated at the latest 5 months after randomization.
For the beginning and ending of the NET, a tolerance
window of 1 week is considered acceptable. Deviations
from this time window will be reported. Individuals
assigned to TAU will be informed about treatment and
counseling options within the local general health care
system immediately after the diagnostic interview.
Six months after the diagnostic interview and the ran-
domized group allocation, the first follow-up interview
will take place (t2). This time point was selected in order
to assure a minimum time interval of 1 month between
the end of KIDNET and the first follow-up interview. In
this way, the diagnostic interview which measures PTSD
symptoms in the past month, will not be biased by the
experience of symptoms during exposure therapy. The
second follow-up interview (t3) is scheduled for 12
months after randomization. For the appointments of
the follow-up interviews, a tolerance window of ± 2
weeks is considered acceptable. Deviations from this
time window will be reported. See Fig. 1 for a schematic
Fig. 1 Participant flow of the trial YOURTREAT. Abbreviations: ADDI Adolescent Discrimination Distress Index, CAPS-CA-5 Clinician-Administered
PTSD Scale for DSM-5 – Child/Adolescent Version, C-SSRS Columbia Suicide Severity Rating Scale, HSCL-37a Hopkins Symptom Checklist-37 for
Refugee Adolescents, KIDNET Narrative Exposure Therapy for Children, PC-PTSD-5 Primary Care Post-traumatic Stress Disorder Screen for DSM-5,
RHS-15 Refugee Health Screener-15, SITBI-G, German version of the Self-Injurious Thoughts and Behaviors Interview, SOMS-7 Screening for
Somatoform Symptoms 7, TAU Treatment As Usual, WAEC War and Adversities Exposure Checklist
Wilker et al. Trials          (2020) 21:185 Page 5 of 16overview of the participant flow through the trial. The
study protocol was written following the Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) Statement 2013 [32]. See Additional file 1 for the
SPIRIT Checklist. The trial was registered at the German
Clinical Trials Registry (Deutsches Register Klinischer
Studien; DRKS) on 15 May 2019 (ID: DRKS00017222).
Outcomes of the trial
Primary outcome
The primary outcome of the trial will be the change
in PTSD symptom severity from the diagnostic inter-
view before treatment initiation (t1) to the follow-up
assignments (t2 and t3). PTSD symptoms will be
measured at each assessment by a structured clinical
interview using the Clinician-administered PTSDScale for DSM-5 – Child/Adolescent Version (CAPS-
CA-5) [33]. The CAPS-CA-5 represents the “gold
standard” for the assessment of PTSD and will be
administered by trained psychologists with the help
of ITAs who can interpret, if required. In order to
standardize the translation of the ITAs, we will
translate the CAPS-CA-5 into the most common
languages spoken by the patients, e.g., Arabic,
Kurdish, Dari and Farsi. Treatment response will be
defined as the results of a mixed linear model with
the CAPS-CA-5 total symptom score as outcome
variable and time and intervention group as well as
their interaction as fixed factors. Furthermore, group
means (KIDNET vs. TAU) will be compared and the
between-group effect sizes (Cohen’s d) will be calcu-
lated at each follow-up assessment.
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In addition, the following continuous secondary out-
comes will be assessed before treatment (t1) and at
each follow-up assessment (t2 and t3). The change of
these secondary outcomes will be also evaluated by
mixed linear models (see the “Statistics” section for
more details).
 Depressive symptoms as well as internalizing and
externalizing behavior will be assessed by the Hopkins
Symptom Checklist-37 for refugee adolescents
(HSCL-37; [34]) The HSCL-37A has been widely used
in refugee populations and has shown excellent
internal consistency (Cronbach’s alpha = .90) as well
as adequate convergent validity with the Strength and
Difficulties Questionnaire (SDQ) [34] of r = .65 [35]
 Suicidal ideation will be assessed by the Columbia
Suicide Severity Rating Scale (C-SSRS) which has a
high internal consistency (α = .93–.94) and allows
for a detailed risk assessment [36]
 Stress caused by discrimination will be assessed by
the Adolescent Discrimination Distress Index
(ADDI) which exhibited adequate internal consistency
for the subscales regarding institutional, educational
and peer discrimination (α = .60–.72) [37]
 Physical health will be assessed by 17 items selected
from the Screening for Somatoform Symptoms 7
(SOMS-7) based on their frequency and sensitivity
to change [38]
Finally, the rate of participants who still meet the diag-
nostic criteria of PTSD according to the CAPS-CA-5, as
well as the PTSD response rate will be assessed at each
follow-up assessment (t2 and t3). The PTSD response
rate will be defined as the rate of participants who show
clinical significant symptom improvement on the CAPS-
CA-5, according to the Reliable Change Index (RCI). In
the absence of an established value of clinical signifi-
cance for the DSM-5 and for populations of children
and youth, the RCI will be calculated from the study
data following the suggestion of Jacobson and Truax
[39]. These dichotomous variables will be analyzed by
Fisher’s exact tests.
Originally, we also aimed at assessing the secondary
outcome acculturation (by the Frankfurt Acculturation
Scale for Youth (FRACC-Y) [40]) as an additional
parameter of integration. However, during the first
diagnostic interviews for the trial, it became evident
that the questions were extremely difficult to answer
for participants with a high symptom burden and
significantly prolonged the duration of the interview.
We therefore decided to omit this secondary outcome
in order to enhance the quality and validity of the
entire interview.Additional measures
Demographic information (including age, gender, in-
formation regarding the flight to Germany, religion,
education and the current living situation) will be
assessed. Furthermore, a short medical anamnesis in-
cluding addiction will take place at each diagnostic
interview.
Adverse and potentially traumatic experiences in-
cluding family and intimate partner violence as well
as war exposure will be assessed by checklists. In
more detail, an adapted version of the War and Ad-
versity Exposure Checklist (WAEC) [41] will be
employed to assess war-related and general traumatic
life events, the short version of the Family Violence
Checklist [42] will be used to measure violent experi-
ences within the family, while an unpublished check-
list created by our work group will be employed to
measure intimate partner violence. Post-migration
living conditions for young refugees will be assessed
by a brief questionnaire developed by the Neuner
Work Group. Furthermore, for accompanied young
refugees whose parents agree to participate, parental
psychopathology will be assessed by the Refugee
Health Screener-15 (RHS-15) [43] and the Primary
Care PTSD Screen for DSM-5 (PC-PTSD-5) [44] and
parental behavior by the Parent Behavior Inventory
[45]. The RHS has been repeatedly used in refugee
populations and shows a high internal consistency
(α = .95), and good convergent validity (r = .88–.91)
with diagnostic proxy instruments for anxiety, depres-
sion and PTSD [43]. The PC-PTSD-5 offers a more
detailed risk assessment for the diagnosis of PTSD
and exhibits a high consistency with a clinical diagno-
sis of PTSD according to the DSM-5 criteria (diag-
nostic accuracy of .86 with a cut-off of 3 [44]).
These variables are included in the diagnostic inter-
view as they might impact children’s mental health and
treatment success.
Exploratory measures
In order to generate hypotheses for forthcoming studies,
the following exploratory outcomes will be assessed:
 Economic status and economic behavior, assessed by
an adaption of the consumption and asset checklist
from Haushofer [46], which was previously
employed in low-income countries
 Non-suicidal self-injury, measured by four items of
the German version of the self-injurious thoughts
and behaviors interview (SITBI-G) [47]
 Diagnosis of complex PTSD, assessed by 13 items
following the definition of the proposed
International Classification of Diseases, edition 11
(ICD-11) criteria [48]
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YOURTREAT is a multi-center study with four partici-
pating centers. Frank Neuner (Bielefeld University) is the
principal investigator (PI) of the trial. Treatments will
take place at the Refugee Outpatient Clinic for Children
and Adolescents at the Medical Center Hamburg
Eppendorf (supervised by Areej Zindler), the Out-
patient Clinic for Psychotherapy of the University of
Konstanz (supervised by Michael Odenwald and Anselm
Crombach), the Outpatient Clinic of the Catholic
University Eichstätt-Ingolstadt (supervised by Rita
Rosner) and the Outpatient Clinic of Bielefeld Univer-
sity (supervised by Frank Neuner). The four study
centers have extensive experience with the treatment
of children and adolescents, including young refugees.
Furthermore, all study centers have established re-
cruitment procedures and referral pathways which
can be employed for the purpose of the current trial.
Only two of the centers (Bielefeld and Konstanz) had
experience with KIDNET before the trial, Eichstätt-
Ingolstatt had tried tf-CBT with refugee children be-
fore, and Hamburg has applied various approaches to
treat young refugees.
Study sample
Subject inclusion and exclusion criteria
Young refugees who fulfill the diagnosis of PTSD
according to the DSM-5 may take part in the study. In
more detail, the inclusion criteria are:
 Being a refugee allocated to a community close to
one of the participating centers but not necessarily
with a permanent permit to stay
 PTSD diagnosis according to CAPS-CA-5
 Age 10–18 years
 Informed consent obtained from participant (if
participant is aged ≥ 16 years) or participant and
caregiver/legal guardian (if participant is aged < 16
years)
For pragmatic reasons (availability of a sufficient num-
ber of ITAs in each language), YOURTREAT will mainly
recruit young refugees from Syria, Iraq and Afghanistan,
the countries, where the majority of refugees who were
seeking asylum in Germany in 2015 originate from.
The following exclusion criteria will be implemented
in the trial:
 Acute risk of harm of self or others requiring
inpatient treatment
 Clinical signs of acute psychotic disorder
 Clinical signs of mental retardation which would
prevent effective psychotherapy
 Concurrent psychotherapeutic treatment Anxiolytic treatment with benzodiazepines as this
medication is known to interfere with exposure-
based psychotherapy (other medication is allowed
and will be monitored)
 High alcohol or drug consumption (≥ 2–3 days of
consumption per week) represents an exclusion
criterion if participants cannot assure their
preparedness and confidence to control their
consumption in favor of the treatment that they
would receive in the framework of the trial
Procedures
Recruitment and eligibility screening
All participating centers have extensive experience with
the recruitment and treatment of children and adoles-
cents, including young refugees. Participants will be
recruited using established recruitment pathways of the
specialized outpatient clinics of the centers.
In addition to these conventional recruitment proce-
dures, the trial aims to introduce an innovative entryway
for young refugees to psychotherapeutic treatment. In
more detail, we plan to train ITAs who cover the most
common languages among the current refugee commu-
nities, from the refugee and migrant community in each
of the four participating. The tasks of the ITAs will be to
interpret the diagnostic interviews and therapy sessions
for all participants who do not speak German fluently in
all study centers. Furthermore, the ITAs can additionally
support the therapeutic process as well as the access to
psychotherapy by accomplishing the following tasks:
 Accompanying young refugees to and from the
therapeutic sessions
 Reducing prejudices against mental health problems
and psychotherapy by awareness-raising in the
refugee community and de-stigmatization of mental
health conditions
 Supporting the recruitment procedure by
approaching young refugees (e.g., in schools), by
providing basic information about health and mental
health, by offering a screening for mental health
symptoms, including PTSD, using the Refugee Health
Screener (RHS-15) [43] and the Primary Care PTSD
Screen for DSM-5 (PC-PTSD-5) [44], and by making
qualified referrals of PTSD cases to the trial or to
other specialists in the health care system
The involvement of ITAs in recruitment and psycho-
therapy will be documented in detail throughout the
trial.
Diagnostic procedures
Diagnostic interviews will be conducted by clinicians
with at least a bachelor’s degree with the help of ITAs
Wilker et al. Trials          (2020) 21:185 Page 8 of 16who interpret the interview. The first diagnostic inter-
view (t1) will comprise the assessment of demographic
information, a short medical anamnesis including addic-
tion, traumatic and adverse event exposure by means of
checklists for war and adversity exposure as well as fam-
ily and intimate partner violence, and post-migration liv-
ing conditions. Furthermore, the diagnosis and symptom
severity of PTSD will be determined by administering
the CAPS-CA-5 [33]. Since our population of young ref-
ugees has experienced multiple traumatic experiences,
the CAPS-CA-5 symptoms can be answered in relation
to several traumatic stressors (and not only to one index
trauma). The CAPS-CA-5 will be amended by additional
items assessing complex PTSD in the same response for-
mat. In order to be eligible for the trial, subjects will
have to meet the diagnostic criteria of PTSD according
to the DSM-5 [6]. This structured interview will be suc-
ceeded by questionnaires assessing depressive symptoms
and internalizing and externalizing symptoms (HSCL-
37A) [35], suicidality (C-SSRS) [36], non-suicidal self-
injury (four items from SITBI-G) [47], economic status
and behavior (adapted from [46]), discrimination (ADDI)
[37] and physical health (excerpts from SOMS-7; Rief
and Hiller [38]). The follow-up interviews will employ
the same questionnaires as detailed above. All diagnostic
data will be recorded directly on Case Report Forms
(CRFs) and are considered to be source data.
For young refugees who are accompanied by either
one parent, both parents, or a legal guardian (who is not
an institutional guardian), we aim at assessing mental
health symptoms of guardians using the RHS and the
PC-PTSD-5. If parents/guardians give their informed
consent to participate, they will be screened for mental
health symptoms by means of the RHS during each diag-
nostic interview of the child. Additionally, demographic
data of the parents/guardians will also be assessed. Fur-
thermore, we will assess the Parent Behavior Inventory
[45] in order to investigate interrelations between
parent/guardian mental health, child mental health and
parental behavior.
See the SPIRIT Figure (Fig. 2) for an overview of the
procedures of the clinical trial YOURTREAT including
enrollment, diagnostic assessments and interventions.Interventions
Narrative Exposure Therapy for Children (KIDNET)
In the trial, 11 sessions of KIDNET will be provided
according to the manual [49]. During the treatment, the
child, with the assistance of the therapist, constructs a
chronological narrative of their whole life with a focus
on the re-construction of the memory of the traumatic
events. While the sessions dedicated to the narration of
the client’s life are individual sessions with the client,parents or caregivers are invited to participate together
with their children in three sessions which concern psy-
choeducation, current problems and future perspectives.
In the first session (100 min), the parent/caregiver
should be present. For the trial, caregivers will be de-
fined as the primary attachment figure. In case of un-
accompanied refugee minors, this will be the caregiver
who the child trusts the most. If the child or adolescent
is unable to identify a single significant caregiver or re-
ports that they does not want a caregiver to participate,
this session takes place in individual format with the pa-
tient. The first session serves the goal of providing psy-
choeducation about PTSD and KIDNET, to motivate the
caregiver for the continuous support of the treatment, to
educate about the internalizing and externalizing stress
reactions of the child and about adaptive responses, as
well as to provide a continuous monitoring of the safety
and well-being of the child throughout the trial. In the
second session of KIDNET (100 min), which is con-
ducted with the client alone, the lifeline exercise is per-
formed in order to obtain a first overview of the
survivor’s life story. A rope symbolizes the course of life,
flowers symbolize positive emotionally arousing events,
while stones symbolize negative experiences, including
traumatic events. The therapist guides the patient to
name the most important life experiences without going
into detail. This is succeeded by the development of the
narration of the patient’s life from birth to present which
may start already in the lifeline session and is continued
in the subsequent therapy sessions. While all significant
events which were brought up in the lifeline exercise are
mentioned in the narration, the most severe traumatic
experiences are treated in detail by means of exposure
therapy in the following sessions (100 min for each ex-
posure therapy session). However, in contrast to other
exposure-based treatments for PTSD which involve re-
peated exposure to one index trauma, a main focus of
KIDNET is the chronological re-construction of autobio-
graphical memory. Furthermore, KIDNET does not
contain a variety of therapeutic components, such as re-
laxation training or cognitive coping, but mainly focuses
on the narrative elements. Next to the sessions dedicated
to the narration of the client’s life, KIDNET will com-
prise an additional session of 50 min together with the
caregiver that can be scheduled during the course of ex-
posure therapy according to the needs of the patient. It
should give the caregiver the opportunity to ask ques-
tions regarding the general therapeutic process and to
discuss implications of the therapy for daily life. Further-
more, options of how the caregiver can further support
the therapeutic process can be discussed. If children or
adolescents prefer to discuss everyday problems without
the presence of the caregiver, this session will be sched-
uled with the patient alone. The process of the narration
Fig. 2 Displayed are the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) for the clinical trial YOURTREAT including
enrollment, diagnostic assessments and interventions. Abbreviations: ADDI Adolescent Discrimination Distress Index, CAPS-CA-5 Clinician-
Administered PTSD Scale for DSM-5 – Child/Adolescent Version, C-SSRS Columbia Suicide Severity Rating Scale, HSCL-37a Hopkins Symptom
Checklist-37 for Refugee Adolescents, KIDNET Narrative Exposure Therapy for Children, PC-PTSD-5 Primary Care Post-traumatic Stress Disorder
Screen for DSM-5, RHS-15 Refugee Health Screener-15, (S)AE (Serious) Adverse Event, SITBI-G German version of the Self-Injurious Thoughts and
Behaviors Interview, SOMS-7 Screening for Somatoform Symptoms 7, TAU Treatment As Usual, WAEC War and Adversities Exposure Checklist.
*Next to established recruitment procedures of the study centers, participants can be recruited and screened by Intercultural Therapy Assistants as an
entryway into the trial. **TAU: patients will be instructed to seek treatment within the general health care system. Therefore, in contrast to KIDNET, the
duration of TAU cannot be specified a priori
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narration of the life story in the 10th session (100 min).
Finally, the last session of the therapy (50 min) will
again include the caregiver and serve to celebrate the
completion of the treatment as well as to discuss ways of
how to cope with residual symptoms and how to furthersupport the client. If desired by the client, the last
session can also take place without the caregiver.
Treatment as usual (TAU)
Children and adolescents allocated to the TAU group
will be referred to the local regular health care system
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group allocation, they will receive detailed information
on how to find psychotherapeutic support in their com-
munity. For children under the age of 16 years, the psy-
choeducation on how to find psychotherapeutic support
in the community will take place in the presence of the
parent or guardian. The interventions provided to the
TAU group will be assessed after each follow-up diag-
nostic assessment.Choice of comparator
The aim of this trial is to test the efficacy of KIDNET
for traumatized refugee children and adolescents in spe-
cialized outpatient clinics with the help of trained ITAs.
For this purpose, it is necessary to compare KIDNET as
provided in the specialized outpatient clinics with the ef-
ficacy of the treatment that would be available without
this module, i.e., a TAU condition. So far, no data exists
regarding the efficacy of TAU in this understudied
population. Policy-makers often point at the limited
evidence regarding the efficacy of trauma treatment for
refugees in industrialized countries to justify the limited
efforts to invest in the improvement of mental health
care for refugees. By comparing a short-term, trauma-
focused intervention with TAU for young refugees in
Germany, the results of this trial could, therefore, inform
major public-health related decisions in Germany; for
example, regarding the usefulness of complementary
treatment structures for refugees and the necessity of
paying costs for interpreters for treatment.Measures against bias
Randomization
Subjects will be randomly allocated to the two arms of
the trial using block-permuted randomization stratified
by center based on computer-generated lists that will be
provided by the independent statistician. Participants
who fulfill the inclusion criteria, including a diagnosis of
PTSD, will be immediately assigned to the interventions.
Diagnosticians for the baseline diagnostic interview will
receive a sequentially numbered, sealed, opaque enve-
lope which will reveal group allocation in case the sub-
ject meets the diagnostic criteria for PTSD. The random
sequence that determines treatment allocation is kept in
a sequence of enumerated sealed envelopes that are pro-
vided to the centers. The envelopes will remain sealed to
ensure concealment of the sequence of treatment alloca-
tions from the research team, assessors and the thera-
pists. At the moment that a patient is assigned to the
trial the single corresponding envelope is opened to
reveal the allocation of the therapist. Block sizes vary
randomly and will not be disclosed in order to assure
concealment.Blinding
Due to the behavioral nature of the intervention, neither
participants nor therapists and ITAs who interpret the
therapy can be blinded. However, the group allocation of
the subjects will be concealed from the independent out-
come assessors who will conduct the follow-up inter-
views. At the beginning of the follow-up interviews,
participants will be instructed not to reveal any informa-
tion related to the group that they have been assigned to
or regarding the therapeutic process. After the comple-
tion of all diagnostic instruments of the follow-up
interview, the independent assessors will complete a
questionnaire asking whether any information regarding
group allocation was revealed in the diagnostic inter-
view. Cases of premature unblinding will be documented
and reported.Measures taken to prevent bias in assessment
The diagnostic interviews will be conducted by specially
trained assessors. As the CAPS-CA-5 [33] serves as the
primary outcome of the study, assessors are extensively
trained in this instrument. During the trial, all interviews
will be videotaped and a random selection of 10% per
site will be checked and rated by an independent evalu-
ator to assess interrater reliability of the CAPS-CA-5.Treatment fidelity
Treatments with KIDNET will be conducted by expert
clinicians (minimum bachelor’s degree) specialized in
the field of psychotraumatology. All study therapists re-
ceive a training in KIDNET which includes a 2-day basic
training including the theoretical background of the
treatment, the practical implementation of KIDNET,
case demonstrations, practical exercise and role-plays in
small groups under the supervision of experienced
KIDNET therapists. This initial training is followed by
an advanced training which includes the discussion and
review of test cases. Furthermore, treatment fidelity dur-
ing the trial will be assured by external NET case con-
sultation with experienced NET therapists after at least
every fourth therapy session as well as regular supervi-
sion and intervision meetings at the study centers. The
frequency of supervision and intervision meetings at the
sites will be recorded throughout the study. In addition,
all sessions will be videotaped and a random selection of
10% per site will be checked by independent raters for
consistency with the treatment manual. Finally, 10% of
the therapy session sheets (which assess the date, dur-
ation, main topics covered in the session, as well as diffi-
culties in the KIDNET process) of all centers will be
reviewed. Observed inconsistencies with the treatment
manual will be documented, but do not constitute an ex-
clusion criterion for the trial.
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In order to avoid systematic drop-out from the study,
participants will receive compensation of 20€ in the
form of a voucher for each follow-up interview. Further-
more, the inclusion of the caregivers and ITAs in the
therapeutic process is intended to increase the cultural
acceptance of the intervention as well as the reliability of
the children and adolescents to show up for the sessions
and diagnostic interviews. Finally, we will analyze all trial
participants as randomized (intention-to-treat analyses).
Data management
Data will be collected at the study centers according to
the General Data Protection Regulation (GDPR). The PI
will appoint and supervise a Data Management Team
(DMT) responsible for all aspects related to data storage,
data integrity and data monitoring during the project
period. Data storage and transfer will be conducted ex-
clusively in an encrypted manner.
The centers will transfer the pseudonymized encrypted
data to a secured server accessible by the DMT. The
DMT will create a merged, pseudonymized dataset only
accessible by themselves which will be stored for the
project duration. Checks for completeness as well as
range checks will be conducted to ensure data integrity.
Furthermore, the DMT will perform at least one site-
monitoring per year at each participating center where
access will be granted to source documents in order to
check for completion of informed consent sheets and
consistency with the entered data.
Statistical analyses will be conducted by the independ-
ent certified biostatistician Theodor May, who will also
supervise the DMT in accordance with the GDPR. For
long-term storage, the anonymized dataset (after dele-
tion of the code list and database lock) will be stored in
the Bielefeld University data repository and provided to
external scientists upon request for further analysis.
Statistics
Power analysis and sample size calculation
The Ruf et al. pilot study [26] achieved a treatment ef-
fect size of 1.9 for NET and 0.3 for the waiting-list con-
trol group. However, we expect that the contrast will be
smaller for this study, as we will have an active control
condition and will provide detailed information to chil-
dren and adolescents from the TAU condition on how
to seek treatment in the regular health care system.
Therefore, we base the effect size calculation at a conser-
vative estimation of a between-group effect size of d =
0.6. To test the hypothesis that a treatment with
KIDNET is more effective than TAU, with a one-sided
alpha level set at 0.05 and a power level of 0.8, we need
to enroll N = 72 subjects (N = 36 per group) into the
present study. Once randomized, loss to follow-up wassmall (generally lower than 5%) in the Ruf et al. study
[26] as well as in other NET studies [50]. Most import-
antly, as the main analysis of the primary outcome
measure will be calculated using a mixed-effects model,
all randomized cases can be included in the statistical
analyses. Therefore, the intended sample size of N = 80
will be sound to answer the research questions of
the trial.
Data analyses
The confirmatory analysis of this study will be calculated as
a mixed-effects model with the CAPS-CA-5 score as the
outcome variable. Mixed models are especially suited for
longitudinal studies as they can account for serial correl-
ation within participants, are relatively robust to randomly
missing data, and can incorporate certain nonrandom miss-
ing data without biasing model estimates. In detail, partici-
pants will be modeled as a random factor (including
random intercepts or random intercepts and slopes), while
time and intervention (KIDNET vs. TAU), as well their
interaction, will be modeled as fixed factors. The hypothesis
that KIDNET is superior to TAU in the treatment of PTSD
will be evaluated by the significance test of the interaction
effect time × intervention.
In case of a significant interaction effect, two planned
general linear hypotheses will be calculated as post-hoc
tests for linear mixed-effect models in order to test
between-group differences at t2 and t3. One-sided p
values will be adjusted for multiple comparisons follow-
ing the Holm procedure.
We will perform an intention-to-treat analysis; that is,
all trial participants will be analyzed as randomized, even
if they discontinue treatment or are unavailable for one
or both of the follow-up interviews. The between-group
effect size (Cohen’s d) will be calculated at each follow-
up assessment (t2 and t3). The intention-to-treat analysis
will be supplemented by a modified intention-to-treat
analysis which will include only those participants who
participated in at least one post-randomization diagnos-
tic interview. Furthermore, participants who were ran-
domized to KIDNET will be included only if they
participated in at least one KIDNET therapy session.
Continuous secondary outcome measures are analyzed
in the same way. In the absence of a valid cut-off score
for clinically significant change or treatment response of
the CAPS-CA-5, the rate of subjects with clinically sig-
nificant improvement as well as worsening based on the
RCI will be compared between groups using Fisher’s
exact tests at the follow-up assessments t2 and t3, separ-
ately. For this purpose, the RCI will be calculated based
on the pre-treatment scores of the study sample follow-
ing the suggestion of Jacobson and Truax [39]. Missing
values due to premature withdraw will be considered as
treatment failure (classified as no response).
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center effects regarding the primary efficacy endpoint
are investigated. For this purpose, the change in CAPS-
CA-5 at t3 (compared to baseline t1) are analyzed explor-
atively using a mixed-effects model that includes partici-
pants as a random factor and center, intervention and
center × intervention as fixed factors. The significance
level will be set at 0.05 for all analyses.
Safety and ethical aspects of the trial
The trial procedures follow the Declaration of Helsinki
and the ICH Guidelines for Good Clinical Practice
(ICH-GCP) [51]. The Ethics Committee of the German
Psychological Association (Deutsche Gesellschaft für
Psychologie, DGPs) approved the study procedures (ap-
proval date: 6 May 2019). Modifications of the protocol,
which are not merely of administrative nature, such as
minor corrections or clarifications, and which might
impact patient safety, ethical aspects of the trial or the
conduct, and scientific evaluation of the trial, will be
submitted as protocol amendments to the Ethics Com-
mittee and require approval. Furthermore, the record at
the trial registry DRKS will be updated and the BMBF
will be informed in case of protocol amendments. Such
amendments will be agreed upon by the PI after consult-
ation with the External Advisory Board.
Safety aspects
So far, no trial has ever reported serious adverse events
(SAEs) caused by psychotherapy of trauma-related disor-
ders in children and adolescents [cf. 52, 53]. Since the
planned treatment study can be, therefore, considered as
safe, we refrain from installing an external Safety Moni-
toring Committee for pragmatic reasons. Instead, we
have appointed a SAE Management Committee consti-
tuted of the lead investigators at the sites (Areej Zindler,
Rita Rosner, Anselm Crombach, Michael Odenwald), the
PI (Frank Neuner), the independent biostatistician and
the External Advisory Board of the trial who will
supervise the safety of the study.
The following dangerous occurrences will be defined
as SAEs in accordance to the ICH-GCP and will be
closely monitored during treatment, and at the follow-
up assessments:
 Attempted suicide
 Event which results in death (suicide or other)
 Life-threatening event
 Event which results in significant disability
All such dangerous events and other safety aspects will
be forwarded to the SAE Management Committee. In
addition, the independent biostatistician will conduct
interim analyses after 30% and 50% of the completed 6-month follow-ups in order to monitor the symptom de-
velopment as well as the occurrence of potential SAEs. If
an SAE is identified, the SAE Management Committee
will investigate whether there is a causal link between
the trial and the SAE. If the SAE Management Commit-
tee decides that further trial participation would be a
safety concern for the patient, the patient will be with-
drawn from the study. In the case of serious safety con-
cerns, the trial will be stopped.
Informed consent procedure
Trained psychologists or physicians (minimum bache-
lor’s degree) will introduce the study procedures to the
participants. Our study population of young refugees is
particularly vulnerable, as their age as well as their lim-
ited knowledge of the German health system might im-
pair their ability to understand the aims and procedures
of the study. In order to assure the comprehension of
the information of the informed consent, and to
standardize the informed consent between the centers,
we have decided to supplement the written informed
consent for the trial by a video which reads out the exact
wording of the informed consent. Furthermore, the in-
formed consent is written in easy language. The written
informed consent will be available in the languages of
the participants. They will detail the study procedures
including diagnostic interviews, randomization, treat-
ment options, potential temporary distress after inter-
views or therapeutic sessions, the possibility of
terminating study participation without any disadvantage,
and data management. Trained psychologists or physi-
cians (minimum bachelor’s degree) will answer questions
arising, and will subsequently obtain written informed
consent from subjects who decide to participate in the
trial. In addition, participants will be asked whether they
want to give informed consent to be contacted for the par-
ticipation in ancillary studies. They will be informed that
this decision does not affect their participation in the
YOURTREAT trial.
Coping with distress
Similar to the re-experiencing symptoms that PTSD
patients experience in everyday life, patients might also
experience high and distressing levels of anxiety or other
unpleasant emotional reactions during assessments or ses-
sions of exposure-based psychotherapy. However, in con-
trast to their everyday experience, where they usually have
to deal with these symptoms on their own, the assessor/
therapist can help them to cope with these reactions, e.g.,
by reinforcing reality or by providing psychoeducation.
Post-trial care
Individuals assigned to the TAU condition who still suf-
fer from PTSD will be offered a treatment with KIDNET
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outpatient clinics. Furthermore, participants who do not
benefit from KIDNET (i.e., still suffer from PTSD at the
last follow-up) will be offered additional treatments at
the participating centers or will be referred to appropri-
ate inpatient or outpatient treatments.
Discussion
In spite of the known detrimental consequences of
trauma originating from war and flight on the mental
and physical health of refugees and their integration into
the host culture, the evidence regarding effective treat-
ment options for this vulnerable population is very lim-
ited [54]. As presented in the literature review in the
introduction, research regarding effective interventions
for young refugees is even sparser. Furthermore, different
barriers including language difficulties, fear of stigma,
and limited knowledge about treatment options for men-
tal health disorders make it difficult for refugees to seek
for help. This is aggravated by bureaucratic obstacles for
psychotherapists to receive payments for psychotherapy
delivered to refugees with unsecure asylum status, and
the required interpreters. Finally, many practitioners are
hesitant to deliver evidence-based PTSD treatments due
to fears of symptom aggravation or treatment discon-
tinuation [55, 56]. In order to counteract these barriers,
and to improve the mental health care for young refu-
gees in the German health care system, systematic stud-
ies are urgently required to inform the scientific and
clinical community as well as public health decisions.
The lack of systematic studies on effective interven-
tions for war-affected refugee children and adolescents
suffering from PTSD might have several reasons. First of
all, the group of adolescents might be of greater risk of
dropping out of treatment trials due to the developmen-
tal tasks in this age period, and unstable mood and mo-
tivation [57]. Even more, young refugees face unstable
living and housing situations and might be relocated at
short notice, making it even more difficult to prevent at-
trition from the trial. Furthermore, a trial with young
refugees requires a close collaboration with, and intense
training of, interpreters from different cultures, demand-
ing additional resources from the research team.
Against this background, the current trial aims at pro-
viding the required knowledge regarding effective treat-
ment options for young refugees. Strengths and innovative
aspects of the trial include (1) the unique study sample of
young refugees hosted in Germany, (2) the systematic as-
sessment of PTSD with the CAPS-CA-5, the gold standard
in the diagnosis of PTSD, (3) the wide range of outcome
measurements, (4) the limited exclusion criteria, which
enhance the external validity of the trial, (5) the short and
pragmatic nature of the delivered treatment, (6) an evalu-
ation of the usual treatment (TAU) within the Germanhealth care system and (7) the implementation and evalu-
ation of a support structure by ITAs, who can interpret
and support the therapeutic process.
A potential limitation of the trial could be the dan-
ger of drop-outs due to the instability of the investi-
gated population. However, a previous study with
young refugees treated with NET also managed to
achieve a low attrition rate [26]. Furthermore, we in-
tend to increase the retention of subjects by closely
collaborating with ITAs from the community of the
study participants as well as with the caregivers of
the young refugees.
In addition, we have to note that the trial is led by
Frank Neuner, one of the developers of (KID)NET.
Therefore, a high treatment loyalty could be stated as a
limitation of the trial. However, it is important to note
that two of the three other centers taking part in the
study have no prior experience with (KID)NET and pre-
viously predominantly used other treatment approaches
for trauma-related disorders. This increases the external
validity and generalizability of the trial.
In sum, this trial has the potential for a scientific im-
pact on major public-health-related decisions in
Germany; for example, regarding the usefulness of com-
plementary treatment structures for refugees and the ne-
cessity to pay costs for interpreters for treatment. In
addition, we expect that this trial can inform the regular
health care system (clinics, psychotherapists in out-
patient clinics, psychotherapist in private practices) as
well as the treatment centers for refugees about the ef-
fect of short-term therapy for refugee children and ado-
lescents and, ultimately, improve the quality of care. As
there is a lack of methodological sound RCTs for refugee
children, we expect that this trial can have a major im-
pact on the guidelines for the treatment of PTSD.Dissemination
The trial results will be disseminated to the scientific
community by publications in international peer-
reviewed journals. The results regarding the primary
outcome of the trial will be published regardless of the
direction and statistical significance of the effect. Next to
the publication of the results in scientific journals, we
will communicate the results to national and inter-
national psychological and psychiatric associations as
well as to the policy-makers in Germany, and the public
media.Trial status
Protocol version 1.5, 19 October 2019.
Recruitment into the trial started in June 2019.
Recruitment will be completed in approximately
May 2021.
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